ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

Company Overview

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory diseases and oncology. Founded in 2002 and headquartered in Singapore, the company has grown to maintain a global footprint with additional offices in the United States, Australia, and Europe. ASLAN leverages its proprietary platform technologies and deep expertise in medicinal chemistry to advance small-molecule and antibody candidates through clinical development.

The company’s lead asset, uzamilimab (ASLAN004), is a humanized monoclonal antibody targeting ICOS ligand for the treatment of immune-mediated conditions such as dermatomyositis and other rare autoimmune diseases. In parallel, ASLAN is advancing ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), through clinical trials in inflammatory bowel disease and other T-cell–mediated disorders. Both programs reflect ASLAN’s strategic focus on addressing high-unmet needs with first- or best-in-class treatments.

ASLAN’s oncology pipeline includes ASLAN101, a small-molecule inhibitor designed to modulate the tumor microenvironment by targeting key kinases involved in immune suppression. This program underscores the company’s commitment to harnessing the immune system to improve cancer outcomes. Across its portfolio, ASLAN collaborates with academic institutions and industry partners to accelerate research and optimize development pathways, ensuring robust scientific rigor and regulatory alignment.

Leadership at ASLAN Pharmaceuticals is headed by Chief Executive Officer Dr. William K.L. Tan, who brings extensive experience in drug discovery and global clinical development. The executive team includes veterans in regulatory affairs, medical affairs, and commercial strategy, positioning the company to efficiently transition candidates from bench to bedside. With a diversified pipeline and a commitment to innovation, ASLAN Pharmaceuticals aims to deliver transformative therapies to patients worldwide.

Key Stats

• Today's Range: $0.60 to $0.60
• 50-Day Range: $0.60 to $0.60
• 52-Week Range: $0.48 to $25.44
• Volume: N/A
• Average Volume: 122,322 shs
• Market Capitalization: $1.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASLN Stock Analysis - Frequently Asked Questions

How have ASLN shares performed this year?

ASLAN Pharmaceuticals' stock was trading at $0.60 at the beginning of the year. Since then, ASLN stock has increased by 0.0% and is now trading at $0.60.

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) posted its earnings results on Friday, August, 11th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($6.40) by $5.52. The firm earned $12 million during the quarter.

When did ASLAN Pharmaceuticals' stock split?

Shares of ASLAN Pharmaceuticals reverse split on the morning of Wednesday, July 3rd 2024.The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did ASLAN Pharmaceuticals IPO?

ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ASLAN Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Tesla (TSLA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Meta Platforms (META), Zoom Communications (ZM), Fulgent Genetics (FLGT) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASLN
• CIK: 1722926
• Web: www.aslanpharma.com
• Phone: 65-6817-9598
• Fax: 65-6225-2419
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($21.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.22 million
• Net Margins: N/A
• Pretax Margin: -290.83%
• Return on Equity: -8,454.87%
• Return on Assets: -121.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $12 million
• Price / Sales: 0.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.50) per share
• Price / Book: -0.09

Miscellaneous

• Outstanding Shares: 2,044,000
• Free Float: 1,948,000
• Market Cap: $1.23 million
• Optionable: Optionable
• Beta: 1.40